Company: GIFLF
Filing Date: 2025-03-31
Form Type: 6-K
Source: 0001104659-25-029805
Chunk: 0

Company: Grifols SA
Filing Date: 2025-03-31
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2025

Commission File No. 001-35193

Grifols, S.A.

(Translation of registrant’s name into English)

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive
office)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.

<div align='center'>Form 20-F x Form 40-F
¨

Grifols, S.A.

TABLE OF CONTENTS</div>

|                             | Grifols, 
 S.A.     |
| Avinguda                    
 de la Generalitat 152-158   
 08174 Sant Cugat del Vallès 
 Barcelona - ESPAÑA          |          |
| Tel. [34] 935 710 500       |          |
| Fax [34] 935 710 267        |          |
| www.grifols.com             |          |

Pursuant to the provisions of article 226 of
the Law 6/2023, of March 17, on Securities Markets and Investment Services, Grifols S.A. ("Grifols" or the "Company")
hereby informs about the following

INSIDE INFORMATION

The Board of Directors of Grifols, S.A. has unanimously
approved that its fully owned subsidiary Grifols Biotest Holdings GmbH submits a public delisting purchase offer to the shareholders
of Biotest AG ("Biotest"). Thus, Grifols Biotest Holdings GmbH announces today its decision to purchase by way of a
public delisting purchase offer all no-par bearer common shares of Biotest and all non-voting bearer preferred shares in Biotest and
its intention to offer EUR 43.00 per each common share and EUR 30.00 per each preferred share. Further, Grifols and Biotest have agreed
that no later than ten (10) workdays prior to